Hip and knee bundles may receive 3-year extension

The Comprehensive Care for Joint Replacement Model, which covers hip and knee joint replacement bundled payments, could see a three-year extension, CMS announced in a proposed rule.

The CJR model began in 2016 and is scheduled to end on Dec. 31, 2020. It aims to cut Medicare expenditures by bundling all care for hip and knee joint replacements into one episode of care while increasing overall quality. The new proposal would keep the bundled payment model through Dec. 31, 2023.

However, the proposal does include other changes to the model and would include outpatient hip and knee replacements into the episode of care definition. The proposal also changes the target price calculation, the reconciliation process, the beneficiary notice requirements, gainsharing caps and the appeals process.

Including outpatient joint replacements changes the definition from the current model that only includes inpatient-only procedures. The bundled payment allows hospitals to cover an entire 90-day episode of care. One 2019 study found the CJR model saved about $1,000 per patient annually, while another study from the New England Journal of Medicine found a 3.1% savings rate, or about $812 per patient.

CMS also proposed changing the target price from three years of claims data to just the most recent one year of data, as well as removing other updates and incorporating risk adjustment into the target price. It also proposed to change the high episode spending cap calculation methodology.

The proposal also makes changes to the reconciliation process, bringing it down from two periods to one period. Currently, hospitals can reconcile payments two months and 14 months after the close of each performance year. Under the proposal, hospitals could conduct a reconciliation period six months after the close of each performance year.

See the proposed rule on the Federal Register here.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.